Global CRISPR Gene Editing Market - GLOBAL:2021

Market Report Coverage :
Start Year : 2020 - Forecast Year : 2030 - Start Value : $1,002.8 Million in 2020 - Forecast Value : $10,825.1 Million by 2030 - CAGR % : 0.27%
Description :
Market Report Coverage - CRISPR Gene EditingMarket Segmentation• Product Type – CRISPR Products: Kits and Enzymes (Vector-Based Cas9, and DNA-Free Cas9), Libraries, Design Tools, Antibodies, and Other Products (CRISPR/Cas9 plasmids, CRISPR Controls, and CRISPR RNAs), CRISPR Services: gRNA Design and Vector Construction, Cell Line and Engineering, Screening Services, and Other Services (Mediated Transcriptome Editing, and Epigenome Editing Services)• Application – Agricultural, Biomedical (Gene Therapy, Drug Discovery, And Diagnostics), Industrial, and Other Applications [Genetically Modified Foods (GM Foods), Biofuel, And Animal (Livestock) Breeding]• End-User - Academic Institutes and Research Centers, Biotechnology Companies, Contract Research Organizations (CROs), and Pharmaceutical and Biopharmaceutical CompaniesRegional Segmentation• North America – U.S., Canada• Europe – Germany, France, Italy, U.K., Spain, Switzerland, and Rest-of-Europe• Asia-Pacific – China, Japan, India, South Korea, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)• Latin America – Brazil, Mexico, and Rest-of-the-Latin America• Rest-of-the-WorldGrowth Drivers• Prevalence of Genetic Disorders and Use of Genome Editing• Government and Private Funding• Technology Advancement in CRISPR Gene EditingMarket Restraints• CRISPR Gene Editing: Off Target Effects and Delivery• Ethical Concerns and Implications with Respect to Human Genome EditingMarket Opportunities• Expanding Gene and Cell Therapy Area• CRISPR Gene Editing Scope in AgricultureKey Companies ProfiledAbcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara BioKey Questions Answered in this Report:• What is CRISPR gene editing?• What is the timeline for the development of CRISPR technology?• How did the CRISPR gene editing market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global CRISPR gene editing market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the patent landscape of this market? What will be the impact of patent expiry on this market?• What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of CRISPR products/therapies? • How is CRISPR gene editing being utilized for the development of therapeutics?• How will the investments by public and private companies and government organizations affect the global CRISPR gene editing market? • What was the market size of the leading segments and sub-segments of the global CRISPR gene editing market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the CRISPR gene editing market during the forecast period?• How will each of the segments of the global CRISPR gene editing market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global CRISPR gene editing market?• What are the major benefits of the implementation of CRISPR gene editing in different field of applications including biomedical research, agricultural research, industrial research, gene therapy, drug discovery, and diagnostics?• What is the market size of the CRISPR gene editing market in different countries of the world?• Which geographical region is expected to contribute to the highest sales of CRISPR gene editing market?• What are the reimbursement scenario and regulatory structure for the CRISPR gene editing market in different regions?• What are the key strategies incorporated by the players of global CRISPR gene editing market to sustain the competition and retain their supremacy?Market OverviewThe development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry. The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineering. However, there are several limitations, which need consideration before clinical applications. Further, many researchers are working on the limitations of CRISPR gene editing technology for better results. The potential of CRISPR gene editing to alter the human genome and modify the disease conditions is incredible but exists with ethical and social concerns. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast.The growth is attributed to the increasing demand in the food industry for better products with improved quality and nutrient enrichment and the pharmaceutical industry for targeted treatment for various diseases. Further, the continued significant investments by healthcare companies to meet the industry demand and growing prominence for the gene therapy procedures with less turnaround time are the prominent factors propelling the growth of the global CRISPR gene editing market.Research organizations, pharmaceutical and biotechnology industries, and institutes are looking for more efficient genome editing technologies to increase the specificity and cost-effectiveness, also to reduce turnaround time and human errors. Further, the evolution of genome editing technologies has enabled wide range of applications in various fields, such as industrial biotech and agricultural research. These advanced methods are simple, super-efficient, cost-effective, provide multiplexing, and high throughput capabilities. The increase in the geriatric population and increasing number of cancer cases, and genetic disorders across the globe are expected to translate into significantly higher demand for CRISPR gene editing market.Furthermore, the companies are investing huge amounts in the research and development of CRISPR gene editing products, and gene therapies. The clinical trial landscape of various genetic and chronic diseases has been on the rise in recent years, and this will fuel the CRISPR gene editing market in the future.Within the research report, the market is segmented based on product type, application, end-user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the application of precision medicine on a global level has created a buzz among companies to invest in the development of novel CRISPR gene editing. Due to the diverse product portfolio and intense market penetration, Merck KGaA, and Thermo Fisher Scientific Inc. have been the pioneers in this field and have been the major competitors in this market. The other major contributors of the market include companies such as Integrated DNA Technologies (IDT), Genscript Biotech Corporation, Takara Bio Inc, Agilent Technologies, Inc., and New England Biolabs, Inc.Based on region, North America holds the largest share of CRISPR gene editing market due to substantial investments made by biotechnology and pharmaceutical companies, improved healthcare infrastructure, rise in per capita income, early availability of approved therapies, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Switzerland Rest-of-EuropeAsia-Pacific China India Australia South Korea Singapore Japan Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin AmericaRest-of-the-Word
Keywords :
crispr gene editing kit, crispr gene editing in humans, crispr gene editing technology, crispr gene editing stock, human crispr gene editing, crispr 9 gene editing, crispr cas gene editing, CRISPR Gene Editing, CRISPR Gene Editing Market, CRISPR Gene Editing Industry, CRISPR Gene Editing Report, CRISPR Gene Editing Market Forecasts, CRISPR Gene Editing Market Trends, CRISPR Gene Editing Market Products, CRISPR Gene Editing Market Applications, CRISPR Gene Editing Market Technology, CRISPR Gene Editing Market Companies, CRISPR Gene Editing Market Analysis, CRISPR Gene Editing Industry Analysis, What is CRISPR Gene Editing, CRISPR Gene Editing Market Definition, CRISPR Gene Editing Market by Product Type, CRISPR Gene Editing Market by Application, CRISPR Gene Editing Market by End User, CRISPR Gene Editing Market by Region, Kits and Enzymes CRISPR Gene Editing Market, Libraries CRISPR Gene Editing Market, Design Tools CRISPR Gene Editing Market, Antibodies CRISPR Gene Editing Market, gRNA Design CRISPR Gene Editing Market, Vector Construction CRISPR Gene Editing Market, Cell Line CRISPR Gene Editing Market, Engineering CRISPR Gene Editing Market, Screening Services CRISPR Gene Editing Market, Agriculture CRISPR Gene Editing Market, Biomedical CRISPR Gene Editing Market, Industrial CRISPR Gene Editing Market, Academic Institutions CRISPR Gene Editing Market, Research Centers CRISPR Gene Editing Market, Biotechnology Companies CRISPR Gene Editing Market, Contract Research Organizations CRISPR Gene Editing Market, Pharmaceutical Companies CRISPR Gene Editing Market, Biopharmaceutical Companies CRISPR Gene Editing Market, North America CRISPR Gene Editing Market, Europe CRISPR Gene Editing Market, Asia-Pacific CRISPR Gene Editing Market, Latin America CRISPR Gene Editing Market
Press Release :
The Global CRISPR Gene Editing Market is projected to reach $10.82 billion by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 26.86% during the period between 2020 and 2030. In the comprehensive study of global CRISPR Gene Editing, BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • Currently over 1,100 products present in the market• Clinical trial data for over 15 clinical trials • Pricing data for over 1,000 products• Evaluation of over 500 brands• Market share analysis• End-user preference data• Detailed global and regional market share analysis including the scrutiny of more than 15 countries • Study of data of more than 20 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis. BIS Research study indicates that the increasing global geriatric population, prevalence of genetic disorders, and increased demand for gene therapeutics, that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global CRISPR gene editing market.The study highlights various emerging opportunities, such as the introduction of CRISPR gene editing and its application in gene and cell therapy development of novel therapies for various chronic, and genetic disorders, and the scope of CRISPR gene editing agriculture, the clinical trial landscape of CRISPR gene editing in China, the U.S, and across the world, challenges in CRISPR gene editing: off target effects and delivery, and massive scope for adoption of CRISPR gene editing in emerging nations that can be leveraged by players operating in the market.Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market by application, target antigen, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study. To emphasize the dominance of the kits and enzymes segment of CRISPR products market segment in the product category of the CRISPR gene editing market in 2020 and 2030, Raviteja Palakurthy, Senior Research Analyst – BIS Research, states, "The reason for market growth and the dominance of CRISPR products market segment can be attributed to the increasing global geriatric population, prevalence of genetic disorders, chronic conditions, rising focus on research and development (R&D) of novel gene therapies, increased government and private funding for improved safety and outcomes provided by the CRISPR gene editing products.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., and Takara Bio.The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers of CRISPR Gene Editing • Distributors of CRISPR Gene Editing • Suppliers of CRISPR Gene Editing • CROs of CRISPR Gene Editing • Research and Academic InstitutionsHow can market intelligence on CRISPR Gene Editing add value to an organization’s decision-making process?• Aids in product development • Aids in analyzing the pipeline of products• Helps in targeting a segment for launching a new product • Offers go to market strategies for the different product categories• Supports in diversifying the product portfolio based on unmet needs• Helps in analyzing technological substitutes and compare the specification• Helps in understanding the clinical trial landscape• Helps to adjust the pricing of upcoming products• Assists in exploring the newer applications• Supports in analyzing the competitors’ funding scenarioInsightful Questions Covered to Enable Companies Take Strategic Decisions• What is CRISPR gene editing?• What is the timeline for the development of CRISPR technology?• How did the CRISPR gene editing market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global CRISPR gene editing market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the patent landscape of this market? What will be the impact of patent expiry on this market?• What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of CRISPR products/therapies? • How is CRISPR gene editing being utilized for the development of therapeutics?• How will the investments by public and private companies and government organizations affect the global CRISPR gene editing market? • What was the market size of the leading segments and sub-segments of the global CRISPR gene editing market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the CRISPR gene editing market during the forecast period?• How will each of the segments of the global CRISPR gene editing market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global CRISPR gene editing market?• What are the major benefits of the implementation of CRISPR gene editing in different field of applications including biomedical research, agricultural research, industrial research, gene therapy, drug discovery, and diagnostics?• What is the market size of the CRISPR gene editing market in different countries of the world?• Which geographical region is expected to contribute to the highest sales of CRISPR gene editing market?• What are the reimbursement scenario and regulatory structure for the CRISPR gene editing market in different regions?• What are the key strategies incorporated by the players of global CRISPR gene editing market to sustain the competition and retain their supremacy?
Companies Mentioned :
Abcam, Inc.Applied StemCell, Inc.Agilent Technologies, Inc.Cellecta, Inc.CRISPR Therapeutics AGThermo Fisher Scientific, Inc.GeneCopoeia, Inc.GeneScript Biotech CorporationHorizon Discovery Group PLCIntegrated DNA Technologies, Inc.Merck KGaANew England Biolabs, Inc.Origene Technologies, Inc.Rockland Immunochemicals, Inc.Synthego CorporationSystem Biosciences LLCToolGen, Inc.Takara Bio
Press Release :
The Global CRISPR Gene Editing Market is projected to reach $10.82 billion by 2030, reveals the premium market intelligence study by BIS Research. The study also highlights that the market is set to witness a CAGR of 26.86% during the period between 2020 and 2030. In the comprehensive study of global CRISPR Gene Editing, BIS Research extensively covers the following:• Market numbers on micro-segments that are influencing the market • Currently over 1,100 products present in the market• Clinical trial data for over 15 clinical trials • Pricing data for over 1,000 products• Evaluation of over 500 brands• Market share analysis• End-user preference data• Detailed global and regional market share analysis including the scrutiny of more than 15 countries • Study of data of more than 20 companiesBesides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, and segmental analysis. BIS Research study indicates that the increasing global geriatric population, prevalence of genetic disorders, and increased demand for gene therapeutics, that not only cure the chronic conditions completely but also improve the quality of life of the patients are the major factors anticipated to contribute to the growth of the global CRISPR gene editing market.The study highlights various emerging opportunities, such as the introduction of CRISPR gene editing and its application in gene and cell therapy development of novel therapies for various chronic, and genetic disorders, and the scope of CRISPR gene editing agriculture, the clinical trial landscape of CRISPR gene editing in China, the U.S, and across the world, challenges in CRISPR gene editing: off target effects and delivery, and massive scope for adoption of CRISPR gene editing in emerging nations that can be leveraged by players operating in the market.Data from different segments of the market has been analyzed minutely to gain a holistic view of the market. These segments include market by application, target antigen, and regions. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study. To emphasize the dominance of the kits and enzymes segment of CRISPR products market segment in the product category of the CRISPR gene editing market in 2020 and 2030, Raviteja Palakurthy, Senior Research Analyst – BIS Research, states, "The reason for market growth and the dominance of CRISPR products market segment can be attributed to the increasing global geriatric population, prevalence of genetic disorders, chronic conditions, rising focus on research and development (R&D) of novel gene therapies, increased government and private funding for improved safety and outcomes provided by the CRISPR gene editing products.”Key insights are drawn from in-depth interviews with the key opinion leaders of more than 20 leading companies, market participants, and vendors. The key players profiled in the report include Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GeneScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., and Takara Bio.The study also offers strategic recommendations that can help organizations in tracking various products, trends, and technologies that are changing the dynamics of the market. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.Who should buy this report?• Manufacturers of CRISPR Gene Editing • Distributors of CRISPR Gene Editing • Suppliers of CRISPR Gene Editing • CROs of CRISPR Gene Editing • Research and Academic InstitutionsHow can market intelligence on CRISPR Gene Editing add value to an organization’s decision-making process?• Aids in product development • Aids in analyzing the pipeline of products• Helps in targeting a segment for launching a new product • Offers go to market strategies for the different product categories• Supports in diversifying the product portfolio based on unmet needs• Helps in analyzing technological substitutes and compare the specification• Helps in understanding the clinical trial landscape• Helps to adjust the pricing of upcoming products• Assists in exploring the newer applications• Supports in analyzing the competitors’ funding scenarioInsightful Questions Covered to Enable Companies Take Strategic Decisions• What is CRISPR gene editing?• What is the timeline for the development of CRISPR technology?• How did the CRISPR gene editing market evolve, and what is its scope in the future?• What are the major market drivers, restraints, and opportunities in the global CRISPR gene editing market?• What are the key developmental strategies that are being implemented by the key players to sustain this market?• What is the patent landscape of this market? What will be the impact of patent expiry on this market?• What is the impact of COVID-19 on this market?• What are the guidelines implemented by different government bodies to regulate the approval of CRISPR products/therapies? • How is CRISPR gene editing being utilized for the development of therapeutics?• How will the investments by public and private companies and government organizations affect the global CRISPR gene editing market? • What was the market size of the leading segments and sub-segments of the global CRISPR gene editing market in 2019?• How will the industry evolve during the forecast period 2020-2030?• What will be the growth rate of the CRISPR gene editing market during the forecast period?• How will each of the segments of the global CRISPR gene editing market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2030?• Which product segment and application segment are expected to register the highest CAGR for the global CRISPR gene editing market?• What are the major benefits of the implementation of CRISPR gene editing in different field of applications including biomedical research, agricultural research, industrial research, gene therapy, drug discovery, and diagnostics?• What is the market size of the CRISPR gene editing market in different countries of the world?• Which geographical region is expected to contribute to the highest sales of CRISPR gene editing market?• What are the reimbursement scenario and regulatory structure for the CRISPR gene editing market in different regions?• What are the key strategies incorporated by the players of global CRISPR gene editing market to sustain the competition and retain their supremacy?
Headline :
Global CRISPR Gene Editing Market to Reach $10.82 Billion by 2030
Table of Contents :
Executive Summary 1 Technology Definition1.1 Inclusion and Exclusion Criteria1.1.1 Inclusions1.1.2 Exclusions2 Research Scope2.1 Key Questions Answered in the Report2.2 Target Audience3 Research Methodology3.1 CRISPR Gene Editing: Research Methodology3.2 Primary Data Sources3.3 Secondary Data Sources3.4 Market Estimation Model3.5 Criteria for Company Profiling4 Market Overview4.1 Introduction4.2 CRISPR Gene Editing Market Approach4.3 Milestones in CRISPR Gene Editing4.4 CRISPR Gene Editing: Delivery Systems4.5 CRISPR Technology: A Potential Tool for Gene Editing4.6 CRISPR Gene Editing Current Scenario4.7 CRISPR Gene Editing Market: Future Potential Application Areas5 Global CRISPR Gene Editing Market, $Million, 2020-20305.1 Pipeline Analysis5.2 CRISPR Gene Editing Market and Growth Potential, 2020-20305.3 Impact of COVID-19 on CRISPR Gene Editing Market5.3.1 Impact of COVID-19 on Global CRISPR Gene Editing Market Growth Rate5.3.1. Impact on CRISPR Gene Editing Companies5.3.2 Clinical Trial Disruptions and Resumptions5.3.3 Application of CRISPR Gene Editing in COVID-196 Market Dynamics6.1 Impact Analysis6.2 Market Drivers6.2.1 Prevalence of Genetic Disorders and Use of Genome Editing6.2.2 Government and Private Funding6.2.3 Technology Advancement in CRISPR Gene Editing6.3 Market Restraints6.3.1 CRISPR Gene Editing: Off Target Effects and Delivery6.3.2 Ethical Concerns and Implications With Respect to Human Genome Editing6.4 Market Opportunities6.4.1 Expanding Gene and Cell Therapy Area6.4.2 CRISPR Gene Editing Scope in Agriculture7 Industry Insights7.1 Introduction7.2 Funding Scenario7.2.1 Funding Scenario: Public Companies7.2.2 Funding Scenario: Private Companies7.2.3 Funding Scenario: Investments by Government Organizations7.3 Regulatory Scenario of CRISPR Gene Editing Market7.3.1 Overview7.3.2 Legal Requirements and Frameworks in the U.S.7.3.3 Clinical Trial Authorization7.3.4 Marketing Authorization7.3.5 USFDA Guidelines for BLA Submission7.3.6 Post-Authorization Regulations7.3.7 Legal Requirements and Frameworks in Europe7.3.7.1 EMA Biologics License Application Process7.3.7.2 Centralized Procedure7.3.7.3 Decentralized Procedure7.3.7.4 Mutual-Recognition Procedure7.3.7.5 National Procedure7.3.8 Legal Requirements and Frameworks in Asia-Pacific7.3.9 Legal Requirements and Framework in Japan7.3.10 Expedited Regulatory Designations Around the World7.4 Pricing of CRISPR Gene Editing7.5 Reimbursement of CRISPR Gene Editing7.5.1 CRISPR Gene Editing: Insurance Coverage in the U.S.8 CRISPR Gene Editing Patent Landscape8.1 Overview8.2 CRISPR Gene Editing Market Patent Landscape: By Application8.3 CRISPR Gene Editing Market Patent Landscape: By Region8.4 CRISPR Gene Editing Market Patent Landscape: By Year9 Global CRISPR Gene Editing Market (by Product Type), $Million9.1 Overview9.2 CRISPR Products9.2.1 Kits and Enzymes9.2.1.1 Vector-Based Cas99.2.1.2 DNA-Free Cas99.2.2 Libraries9.2.3 Design Tools9.2.4 Antibodies9.2.5 Other Products9.3 CRISPR Services9.3.1 gRNA Design and Vector Construction9.3.2 Cell Line and Engineering9.3.3 Screening Services9.3.4 Other Services10 CRISPR Gene Editing Market (by Application), $Million10.1 Overview10.2 Agriculture10.3 Biomedical10.3.1 Gene Therapy10.3.2 Drug Discovery10.3.3 Diagnostics10.4 Industrial10.5 Other Applications11 Global CRISPR Gene Editing Market (by End User)11.1 Academic Institutions and Research Centers11.2 Biotechnology Companies11.3 Contract Research Organizations (CROs)11.4 Pharmaceutical and Biopharmaceutical Companies12 Global CRISPR Gene Editing Market (by Region)12.1 Introduction12.1.1 Global CRISPR Gene Editing Market (by Region), 2019-203012.2 North America12.2.1 U.S.12.2.1.1 U.S. CRISPR Gene Editing Market (by Application), 2019-203012.2.2 Canada12.2.2.1 Canada CRISPR Gene Editing Market (by Application), 2019-203012.3 Europe12.3.1 U.K.12.3.1.1 U.K. CRISPR Gene Editing Market (by Application), 2019-203012.3.2 Germany12.3.2.1 Germany CRISPR Gene Editing Market (by Application), 2019-203012.3.3 France12.3.3.1 France CRISPR Gene Editing Market (by Application), 2019-203012.3.4 Spain12.3.4.1 Spain CRISPR Gene Editing Market (by Application), 2019-203012.3.5 Italy12.3.5.1 Italy CRISPR Gene Editing Market (by Application), 2019-203012.3.6 Switzerland12.3.6.1 Switzerland CRISPR Gene Editing Market (by Application), 2019-203012.3.7 Rest-of-Europe12.3.7.1 Rest-of-Europe CRISPR Gene Editing Market (by Application), 2019-203012.4 Asia-Pacific12.4.1 Japan12.4.1.1 Japan CRISPR Gene Editing Market (by Application), 2019-203012.4.2 China12.4.2.1 China CRISPR Gene Editing Market (by Application), 2019-203012.4.3 South Korea12.4.3.1 South Korea CRISPR Gene Editing Market (by Application), 2019-203012.4.4 Singapore12.4.4.1 Singapore CRISPR Gene Editing Market (by Application), 2019-203012.4.5 Australia12.4.5.1 Australia CRISPR Gene Editing Market (by Application), 2019-203012.4.6 India12.4.6.1 India CRISPR Gene Editing Market (by Application), 2019-203012.4.7 Rest-of-APAC12.4.7.1 Rest-of-APAC CRISPR Gene Editing Market (by Application), 2019-203012.5 Latin America12.5.1 Brazil12.5.1.1 Brazil CRISPR Gene Editing Market (by Application), 2019-203012.5.2 Mexico12.5.2.1 Mexico CRISPR Gene Editing Market (by Application), 2019-203012.5.3 Rest-of-Latin America12.5.3.1 RoLA CRISPR Gene Editing Market (by Application), 2019-203012.6 Rest-of-the-World12.6.1 RoW CRISPR Gene Editing Market (by Application), 2019-203013 Competitive Landscape13.1 Key Developments and Strategies13.1.1 Overview13.1.1.1 Regulatory and Legal Developments13.1.1.2 Synergistic Activities13.1.1.3 M&A Activities13.1.1.4 Funding Activities13.2 Market Share Analysis13.3 Growth Share Analysis14 Company Profiles14.1 Overview14.2 Abcam, Inc.14.2.1 Company Overview14.2.2 Role of Abcam, Inc. in the Global CRISPR Gene Editing Market14.2.3 Financials14.2.4 SWOT Analysis14.3 Applied StemCell, Inc.14.3.1 Company Overview14.3.2 Role of Applied StemCell, Inc. in the Global CRISPR Gene Editing Market14.3.3 SWOT Analysis14.4 Agilent Technologies, Inc.14.4.1 Company Overview14.4.2 Role of Agilent Technologies, Inc. in the Global CRISPR Gene Editing Market14.4.3 Financials14.4.4 R&D Expenditure, 2017-201914.4.5 SWOT Analysis14.5 Cellecta, Inc.14.5.1 Company Overview14.5.2 Role of Cellecta, Inc. in the Global CRISPR Gene Editing Market14.5.3 SWOT Analysis14.6 CRISPR Therapeutics AG14.6.1 Company Overview14.6.2 Role of CRISPR Therapeutics AG in the Global CRISPR Gene Editing Market14.6.3 Financials14.6.4 R&D Expenditure, 2017-201914.6.5 SWOT Analysis14.7 Thermo Fisher Scientific, Inc. INC14.7.1 Company Overview14.7.2 Role of Thermo Fisher Scientific, Inc. in the Global CRISPR Gene Editing Market14.7.3 Financials14.7.4 R&D Expenditure, 2017-201914.7.5 SWOT Analysis14.8 GeneCopoeia, Inc.14.8.1 Company Overview14.8.2 Role of GeneCopoeia, Inc. in the Global CRISPR Gene Editing Market14.8.3 SWOT Analysis14.9 GeneScript Biotech Corporation14.9.1 Company Overview14.9.2 Role of GenScript Biotech in the Global CRISPR Gene Editing Market14.9.3 Financials14.9.4 SWOT Analysis14.1 Horizon Discovery Group PLC14.10.1 Company Overview14.10.2 Role of Horizon Discovery Group PLC in the Global CRISPR Gene Editing Market14.10.3 Financials14.10.4 SWOT Analysis14.11 Integrated DNA Technologies, Inc.14.11.1 Company Overview14.11.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market14.11.3 SWOT Analysis14.12 Merck KGaA14.12.1 Company Overview14.12.2 Role of Merck KGaA in the Global CRISPR Gene Editing Market14.12.3 Financials14.12.4 SWOT Analysis14.13 New England Biolabs, Inc.14.13.1 Company Overview14.13.2 Role of Integrated DNA Technologies, Inc. in the Global CRISPR Gene Editing Market14.13.3 SWOT Analysis14.14 Origene Technologies, Inc.14.14.1 Company Overview14.14.2 Role of Origene Technologies, Inc. in the Global CRISPR Gene Editing Market14.14.3 SWOT Analysis14.15 Rockland Immunochemicals, Inc.14.15.1 Company Overview14.15.2 Role of Rockland Immunochemicals, Inc. in the Global CRISPR Gene Editing Market14.15.3 SWOT Analysis14.16 Synthego Corporation14.16.1 Company Overview14.16.2 Role of Synthego Corporation in the Global CRISPR Gene Editing Market14.16.3 SWOT Analysis14.17 System Biosciences LLC14.17.1 Company Overview14.17.2 Role of System Biosciences LLC in the Global CRISPR Gene Editing Market14.17.3 SWOT Analysis14.18 ToolGen, Inc.14.18.1 Company Overview14.18.2 Role of ToolGen, Inc. in the Global CRISPR Gene Editing Market14.18.3 SWOT Analysis14.19 Takara Bio14.19.1 Company Overview14.19.2 Role of Takara Bio in the Global CRISPR Gene Editing Market14.19.3 Financials14.19.4 SWOT AnalysisList of Tables Table 1: Leading Players in Global CRISPR Gene Editing MarketTable 4.1: CRISPR Exhibits Most Potential as Compared to Other Gene Editing TechnologiesTable 5.1: Impact of COVID-19 on CRISPR Clinical TrialsTable 6.1: Private Company Investments in CRISPR Gene EditingTable 7.1: Total Funding Received and IPO by CRISPR Gene Editing Public CompaniesTable 7.2: Funding Scenario of Government OrganizationsTable 7.3: Expedited Regulatory Designations Around the WorldTable 7.4: Cost of CRISPR Editing ExperimentTable 7.5: Cost of CRISPR Gene EditingList of Figures Figure 1: Global Total Burden of Diseases by CauseFigure 2: Global Geriatric Population by AgeFigure 3: CRISPR Gene Editing: Potential Areas of InterestFigure 4: Global CRISPR Gene Editing MarketFigure 5: Global CRISPR Gene Editing Market (by Product Type), $Million, 2019, 2025, and 2030Figure 6: Global CRISPR Gene Editing: Impact AnalysisFigure 7: Share of Key Developments and Strategies, June 2015-June 2020Figure 8: Global CRISPR Gene Editing Market (by Product Type), $Million, 2019 and 2030Figure 9: Global CRISPR Gene Editing Market (by Application), $Million, 2019 and 2030Figure 10: Global CRISPR Gene Editing Market (by End User), $Million, 2019 and 2030Figure 11: Global CRISPR Gene Editing Market (by Region), 2019 and 2030Figure 2.1: Global CRISPR Gene Editing Market SegmentationFigure 3.1: Global CRISPR Gene Editing Market MethodologyFigure 3.2: Primary Research MethodologyFigure 3.3: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.4: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: CRISPR-Cas Systems and its ClassificationFigure 4.2: CRISPR Gene Editing ApproachFigure 4.3: Key Milestones in CRISPR Gene EditingFigure 4.5: CRISPR Gene Editing Most Potential Future Application AreasFigure 5.1: CRISPR Gene Editing Clinical Trials (by Phase)Figure 5.2: Global CRISPR Gene Editing Market, 2019-2030Figure 5.3: COVID-19 Status GloballyFigure 5.4: COVID-19 Progression CurveFigure 5.5: Most Impacted Practices in CRISPR Gene EditingFigure 5.6: COVID-19 Impact on CRISPR Gene Editing MarketFigure 5.7: Application of CRISPR-Cas Systems in COVID-19Figure 6.1: Global CRISPR Gene Editing: Impact AnalysisFigure 6.2: Rise in CRISPR PubMed Publications During 2012-2017 Expresses Preference Over Other Gene Editing TechnologiesFigure 6.3: NIH Funding for CRISPR-Related ResearchFigure 6.4: Technological Advancement Using CRISPR SystemsFigure 6.5: Major Ethical Concerns of CRISPR Gene EditingFigure 6.6: CRISPR Gene Editing Applications in Cell and Gene TherapyFigure 6.7: Number of Publications on CRISPR Gene Editing in Plant Genome Editing With Agricultural Applications – by RegionFigure 7.1: Top Funded CRISPR Gene Editing Public Companies, 2015-2020Figure 7.2: Top-Funded CRISPR Gene Editing Private CompaniesFigure 7.3: Clinical Trial Authorization for CRISPR Gene EditingFigure 7.4: Steps for Obtaining Marketing AuthorizationFigure 7.5: USFDA Review TimelineFigure 7.6: EMA Review TimelineFigure 8.1: Global CRISPR Gene Editing Market Patents (by Application)Figure 8.2: The U.S. and China Dominated Patents (by Application)Figure 8.3: Global CRISPR Gene Editing Market Patents (by Region)Figure 8.4: Global CRISPR Gene Editing Market Patents (by Year)Figure 9.1: Revenue Contribution of Different Segments, 2020 and 2030Figure 9.2: Revenue Contribution of CRISPR Products Segments, 2020 and 2030Figure 9.3: Revenue Contribution of Kits and Enzymes Products Segments, 2020 and 2030Figure 9.4: Global CRISPR Gene Editing Market (Kits and Enzymes), 2019-2030Figure 9.5: Global CRISPR Gene Editing Market (Vector-Based Cas9), 2019-2030Figure 9.6: Global CRISPR Gene Editing Market (DNA-Free Cas9), 2019-2030Figure 9.7: Global CRISPR Gene Editing Market (Libraries), 2019-2030Figure 9.8: Global CRISPR Gene Editing Market (Design Tools), 2019-2030Figure 9.9: Global CRISPR Gene Editing Market (Antibodies), 2019-2030Figure 9.10: Global CRISPR Gene Editing Market (Other Products), 2019-2030Figure 9.11: Revenue Contribution of CRISPR Services Segments, 2020 and 2030Figure 9.12: Global CRISPR Gene Editing Market (gRNA Design and Vector Construction), 2019-2030Figure 9.13: Global CRISPR Gene Editing Market (Cell Line and Engineering), 2019-2030Figure 9.14: Global CRISPR Gene Editing Market (Screening Services), 2019-2030Figure 9.15: Global CRISPR Gene Editing Market (Other Services), 2019-2030Figure 10.1: Revenue Contribution of Different Segments (by Application), 2020 and 2030Figure 10.2: CRISPR Gene Editing Market (Agriculture), 2019-2030Figure 10.3: Revenue Contribution of Different Segments (by Biomedical), 2020 and 2030Figure 10.4: CRISPR Gene Editing Market (Gene Therapy), 2019-2030Figure 10.5: CRISPR Gene Editing Market (Drug Discovery), 2019-2030Figure 10.6: CRISPR Gene Editing Market (Diagnostics), 2019-2030Figure 10.7: CRISPR Gene Editing Market (Industrial), 2019-2030Figure 10.8: CRISPR Gene Editing Market (Other Applications), 2019-2030Figure 11.1: Revenue Contribution of End User Segments, 2020 and 2030Figure 11.2: CRISPR Gene Editing Market (by Academic Institutions and Research Centers), 2019-2030Figure 11.3: CRISPR Gene Editing Market (by Biotechnology Company), 2019-2030Figure 11.4: CRISPR Gene Editing Market (by Contract Research Organization), 2019-2030Figure 11.5: CRISPR Gene Editing Market (by Pharmaceutical and Biopharmaceutical Company), 2019-2030Figure 12.1: Global CRISPR Gene Editing Market (by Region)Figure 12.2: Global CRISPR Gene Editing Market (by Region), 2019-2030Figure 12.3: Global CRISPR Gene Editing Market (by Region), 2019-2030Figure 12.4: North America CRISPR Gene Editing Market, 2019-2030Figure 12.5: North America: Market DynamicsFigure 12.6: Revenue Contributions of Various Countries in North America, 2019 and 2030Figure 12.7: U.S. CRISPR Gene Editing Market, 2019-2030Figure 12.8: U.S. CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.9: Canada CRISPR Gene Editing Market, 2019-2030Figure 12.10: Canada CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.11: Europe CRISPR Gene Editing Market, 2019-2030Figure 12.12: Europe: Market DynamicsFigure 12.13: Revenue Contributions of Various Countries in Europe, 2019 and 2030Figure 12.14: U.K. CRISPR Gene Editing Market, 2019-2030Figure 12.15: U.K. CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.16: Germany CRISPR Gene Editing Market, 2019-2030Figure 12.17: Germany CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.18: France CRISPR Gene Editing Market, 2019-2030Figure 12.19: France CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.20: Spain CRISPR Gene Editing Market, 2019-2030Figure 12.21: Spain CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.22: Italy CRISPR Gene Editing Market, 2019-2030Figure 12.23: Italy CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.24: Switzerland CRISPR Gene Editing Market, 2019-2030Figure 12.25: Switzerland CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.26: Rest-of-Europe CRISPR Gene Editing Market, 2019-2030Figure 12.27: Rest-of-Europe CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.28: Asia-Pacific CRISPR Gene Editing Market, 2019-2030Figure 12.29: Asia-Pacific: Market DynamicsFigure 12.30: Revenue Contributions of Various Countries in Asia-Pacific, 2019 and 2030Figure 12.31: Japan CRISPR Gene Editing Market, 2019-2030Figure 12.32: Japan CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.33: China CRISPR Gene Editing Market, 2019-2030Figure 12.34: China CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.35: South Korea CRISPR Gene Editing Market, 2019-2030Figure 12.36: South Korea CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.37: Singapore CRISPR Gene Editing Market, 2019-2030Figure 12.38: Singapore CRISPR gene editing Market (by Application), 2019-2030Figure 12.39: Australia CRISPR Gene Editing Market, 2019-2030Figure 12.40: Australia CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.41: Australia CRISPR Gene Editing Market, 2019-2030Figure 12.42: India CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.43: Rest-of-APAC CRISPR Gene Editing Market, 2019-2030Figure 12.44: Rest-of-APAC CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.45: Latin America CRISPR Gene Editing Market, 2019-2030Figure 12.46: Latin America: Market DynamicsFigure 12.47: Revenue Contributions of Various Countries in Latin America, 2019 and 2030Figure 12.48: Brazil CRISPR Gene Editing Market, 2019-2030Figure 12.49: Brazil CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.50: Mexico CRISPR Gene Editing Market, 2019-2030Figure 12.51: Mexico CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.52: RoLA CRISPR Gene Editing Market, 2019-2030Figure 12.53: RoLA CRISPR Gene Editing Market (by Application), 2019-2030Figure 12.54: RoW CRISPR Gene Editing market, 2019-2030Figure 12.55: RoW CRISPR Gene Editing Market (by Application), 2019-2030Figure 13.1: Share of Key Developments and Strategies, July 2015-July 2020Figure 13.2: Regulatory and Legal Developments Share (by Company), July 2015-July 2020Figure 13.3: Synergistic Activities (by Company), July 2015-July 2020Figure 13.4: Company Share (by Synergistic Activity), July 2015-July 2020Figure 13.5: M&A Activities Share (by Company), July 2015-July 2020Figure 13.6: Funding Activities (by Company), July 2015-July 2020Figure 13.7: Market Share Analysis (by Company), 2018 and 2019Figure 13.8: Growth Share Matrix for Global CRISPR Gene Editing Market (by Company), 2019Figure 14.1: Total Number of Companies ProfiledFigure 14.2: Abcam, Inc.: Overall Product PortfolioFigure 14.3: Abcam, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.4: Abcam, Inc.: Overall Financials, 2017-2019Figure 14.5: Abcam, Inc. Net Revenue (by Business Segment), 2017-2019Figure 14.6: Abcam, Inc. (by Region), 2017-2019Figure 14.7: Abcam, Inc. R&D Expense, 2017-2019Figure 14.8: Abcam, Inc.: SWOT AnalysisFigure 14.9: Applied StemCell, Inc.: Overall Product PortfolioFigure 14.10: Applied StemCell, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.11: Applied StemCell, Inc.: SWOT AnalysisFigure 14.12: Agilent Technologies, Inc.: Overall Product PortfolioFigure 14.13: Agilent Technologies, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.14: Agilent Technologies, Inc.: Overall Financials, 2017-2019Figure 14.15: Agilent Technologies, Inc. Net Revenue (by Business Segment), 2017-2019Figure 14.16: Agilent Technologies, Inc. (by Region), 2017-2019Figure 14.17: Agilent Technologies, Inc. R&D Expense, 2017-2019Figure 14.18: Abcam, Inc.: SWOT AnalysisFigure 14.19: Cellecta, Inc.: Overall Product PortfolioFigure 14.20: Cellecta, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.21: Cellecta, Inc.: SWOT AnalysisFigure 14.22: CRISPR Therapeutics: Overall Product PortfolioFigure 14.23: CRISPR Therapeutics: CRISPR Gene Editing Product Portfolio PipelineFigure 14.24: CRISPR Therapeutics: Overall Financials, 2017-2019Figure 14.25: CRISPR Therapeutics AGR&D Expenditure, 2017-2019Figure 14.26: CRISPR Therapeutics: SWOT AnalysisFigure 14.27: Thermo Fisher Scientific, Inc.: Overall Product PortfolioFigure 14.28: Thermo Fisher Scientific, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.29: Thermo Fisher Scientific, Inc.: Overall Financials, 2017-2019Figure 14.30: Thermo Fisher Scientific, Inc. Net Revenue (by Business Segment), 2017-2019Figure 14.31: Thermo Fisher Scientific, Inc. Net Revenue (by Region), 2017-2019Figure 14.32: Thermo Fisher Scientific, Inc.: R&D Expense, 2017-2019Figure 14.33: Thermo Fisher Scientific, Inc.: SWOT AnalysisFigure 14.34: GeneCopoeia, Inc.: Overall Product PortfolioFigure 14.35: GeneCopoeia, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.36: GeneCopoeia, Inc.: SWOT AnalysisFigure 14.37: GeneScript Biotech: Overall Product PortfolioFigure 14.38: GenScript Biotech: CRISPR Gene Editing Product Portfolio CategoryFigure 14.39: GenScript Biotech: Overall Financials, 2017-2019Figure 14.40: GenScript Net Revenue (by Business Segment), 2017-2019Figure 14.41: GenScript Biotech Net Revenue (by Region), 2017-2019Figure 14.42: GenScript Biotech: R&D Expense, 2017-2019Figure 14.43: GenScript Biotech: SWOT AnalysisFigure 14.44: Horizon Discovery Group PLC: Overall Product PortfolioFigure 14.45: Horizon Discovery Group PLC: CRISPR Gene Editing Product Portfolio CategoryFigure 14.46: Horizon Discovery Group PLC: Overall Financials, 2017-2019Figure 14.47: Horizon Discovery Group PLC Net Revenue (by Business Segment), 2017-2019Figure 14.48: Horizon Discovery Group PLC Net Revenue (by Region), 2017-2019Figure 14.49: Horizon Discovery Group PLC: R&D Expense, 2017-2019Figure 14.50: Horizon Discovery Group PLC: SWOT AnalysisFigure 14.51: Integrated DNA Technologies, Inc.: Overall Product PortfolioFigure 14.52: Integrated DNA Technologies, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.53: Integrated DNA Technologies, Inc.: SWOT AnalysisFigure 14.54: Merck KGaA: Overall Product PortfolioFigure 14.55: Merck KGaA: CRISPR Gene Editing Product Portfolio CategoryFigure 14.56: Merck KGaA: Overall Financials, 2017-2019Figure 14.57: Merck KGaA Net Revenue (by Business Segment), 2017-2019Figure 14.58: Merck KGaA Net Revenue (by Region), 2017-2019Figure 14.59: Merck KGaA: R&D Expense, 2017-2019Figure 14.60: Merck KGaA: SWOT AnalysisFigure 14.61: New England Biolabs, Inc.: Overall Product PortfolioFigure 14.62: New England Biolabs, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.63: New England Biolabs, Inc.: SWOT AnalysisFigure 14.64: Origene Technologies, Inc.: Overall Product PortfolioFigure 14.65: Origene Technologies, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.66: Origene Technologies, Inc.: SWOT AnalysisFigure 14.67: Rockland Immunochemicals, Inc.: Overall Product PortfolioFigure 14.68: Rockland Immunochemicals, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.69: Rockland Immunochemicals, Inc.: SWOT AnalysisFigure 14.70: Synthego Corporation: Overall Product PortfolioFigure 14.71: Synthego Corporation: CRISPR Gene Editing Product Portfolio CategoryFigure 14.72: Synthego Corporation: SWOT AnalysisFigure 14.73: System Biosciences LLC: Overall Product PortfolioFigure 14.74: System Biosciences LLC: CRISPR Gene Editing Product Portfolio CategoryFigure 14.75: System Biosciences LLC: SWOT AnalysisFigure 14.76: ToolGen, Inc.: Overall Product PortfolioFigure 14.77: ToolGen, Inc.: CRISPR Gene Editing Product Portfolio CategoryFigure 14.78: ToolGen, Inc.: SWOT AnalysisFigure 14.79: Takara Bio: Overall Product PortfolioFigure 14.80: Takara Bio: CRISPR Gene Editing Product Portfolio CategoryFigure 14.81: Takara Bio: Overall Financials, 2017-2019Figure 14.82: Takara Bio Net Revenue (by Business Segment), 2017-2019Figure 14.83: Takara Bio Net Revenue (by Region), 2017-2019Figure 14.84: Takara Bio: R&D Expense, 2017-2019Figure 14.85: Takara Bio: SWOT Analysis